DGIdb - DRD2 Gene Record

DRD2 1813 Druggable Genome

Alternate Names:

1813
DOPAMINE RECEPTOR D2
DRD2
D2DR
D2R
126450
3023
ENSG00000149295
OTTHUMG00000167717
Dopamine D2 receptor
D(2) dopamine receptor
DRD2_HUMAN
P14416
PA27478
D(2) DOPAMINE RECEPTOR (DOPAMINE D2 RECEPTOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P14416]
T67162

Gene Info:

Interpro Name	GPCR, rhodopsin-like, 7TM
Interpro Short Name	7TM_GPCR_Rhodpsn
Human Readable Name	DRUGGABLE GENOME
Uniprot Evidence	1: Evidence at protein level
Uniprot Status	Swiss-Prot
Interpro Acc	IPR000276
Human Readable Name	G PROTEIN COUPLED RECEPTOR
Interpro Type	Family
Target Class	Receptors
Target Subclass	GPCR
Target Subclass	Rhodopsin
Target Main Class	Receptors
Transmembrane Helix Count	7
Gene Biotype	PROTEIN_CODING

(9 More Sources)

Gene Categories: Category Details

G PROTEIN COUPLED RECEPTOR
DRUGGABLE GENOME

Publications:

Shahid et al., 2009, Asenapine: a novel psychopharmacologic agent with a unique human receptor signature., J. Psychopharmacol. (Oxford)
Tadori et al., 2011, Functional potencies of dopamine agonists and antagonists at human dopamine D₂ and D₃ receptors., Eur. J. Pharmacol.
Citrome, 2011, Role of sublingual asenapine in treatment of schizophrenia., Neuropsychiatr Dis Treat
Arranz MJ et al., 1998, Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response., Pharmacogenetics
Eum S et al., 2017, Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report., BMC Psychiatry
Sukasem C et al., 2016, Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders., J Clin Psychopharmacol
Blasi G et al., 2015, Variation in Dopamine D2 and Serotonin 5-HT2A Receptor Genes is Associated with Working Memory Processing and Response to Treatment with Antipsychotics., Neuropsychopharmacology
López-Rodríguez R et al., 2013, Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers., Pharmacogenomics
Roke Y et al., 2013, The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys., Pharmacogenet Genomics
Houston JP et al., 2012, Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia., J Clin Psychiatry
Houston J et al., 2011, Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women., Psychiatry Res
Müller DJ et al., 2012, Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain., Pharmacogenomics J
Hong CJ et al., 2010, Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment., Pharmacogenet Genomics
Zhang JP et al., 2010, D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis., Am J Psychiatry
Yasui-Furukori N et al., 2008, Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients., Prog Neuropsychopharmacol Biol Psychiatry
Bakker PR et al., 2008, Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions., Mol Psychiatry
Alenius M et al., 2008, Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting., J Psychiatr Res
Zai CC et al., 2007, Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients., Mol Psychiatry
Suzuki A et al., 2001, The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients., Pharmacogenetics
Batra S, 1976, Unconjugated estradiol in the myometrium of pregnancy., Endocrinology
Ohara K et al., 1998, Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia., Psychiatry Res
Li T et al., 1998, Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia., Schizophr Res
Shen YC et al., 2009, Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients., J Psychiatr Res
Xing Q et al., 2007, The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients., Int J Neuropsychopharmacol
Lencz et al., 2006, DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients., Am J Psychiatry
Lerman C et al., 2006, Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials., Neuropsychopharmacology
Hwang R et al., 2005, Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations., Psychopharmacology (Berl)
Wu et al., 2005, Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients., Neurosci. Lett.
Yamanouchi Y et al., 2003, Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone., Pharmacogenomics J
Li T et al., 2002, Allelic association analysis of the dopamine D2, D3, 5-HT2A, and GABA(A)gamma2 receptors and serotonin transporter genes with heroin abuse in Chinese subjects., Am J Med Genet
Thacker et al., 2006, The effects of adulthood olanzapine treatment on cognitive performance and neurotrophic factor content in male and female rats neonatally treated with quinpirole., Eur. J. Neurosci.
Weizman et al., 2003, The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms., Eur. J. Pharmacol.
Naiker et al., 2006, Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat., Eur. J. Pharmacol.
Uchida et al., 2007, Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine., Life Sci.
Jordan et al., 2007, In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling., J. Psychopharmacol. (Oxford)
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry
Brafford MV et al., 2014, Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting., J Adv Pract Oncol
Lipska et al., 2003, Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs., Eur. J. Neurosci.
Young et al., 2004, Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele., Br J Psychiatry
Green et al., 2002, Treatment of schizophrenia and comorbid substance use disorder., Curr Drug Targets CNS Neurol Disord
Stonehouse et al., 2005, Bromocriptine and clozapine regulate dopamine 2 receptor gene expression in the mouse striatum., J. Mol. Neurosci.
Takano et al., 2006, Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations., Prog. Neuropsychopharmacol. Biol. Psychiatry
Tresadern G et al., 2011, Molecular properties affecting fast dissociation from the D2 receptor., Bioorg Med Chem
Rascol O et al., 2007, Dopamine agonists., Handb Clin Neurol
de Mey et al., 1991, Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist., Br J Clin Pharmacol
Iida et al., 1999, Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist., Brain Res.
Matsukawa et al., 2007, Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats., Brain Res.
Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem
Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy
Shill HA et al., 2009, Update on ropinirole in the treatment of Parkinson's disease., Neuropsychiatr Dis Treat
Mørk et al., 2009, Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved., Psychopharmacology (Berl.)
Cincotta et al., 2010, Emerging role of sertindole in the management of schizophrenia., Neuropsychiatr Dis Treat
Lindström et al., 2006, Sertindole: efficacy and safety in schizophrenia., Expert Opin Pharmacother
Seeman, 2008, Dopamine D2(High) receptors moderately elevated by sertindole., Synapse
Cavallotti et al., Age-related changes in dopamine D2 receptors in rat heart and coronary vessels., Clin. Exp. Pharmacol. Physiol.
Jaber et al., 1994, Differential influence of haloperidol and sulpiride on dopamine receptors and peptide mRNA levels in the rat striatum and pituitary., Brain Res. Mol. Brain Res.
Newman AH et al., 2012, Molecular determinants of selectivity and efficacy at the dopamine D3 receptor., J Med Chem
Auclair et al., 2007, Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats., Psychopharmacology (Berl.)
Newman-Tancredi et al., 2007, Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics., Curr Opin Investig Drugs
Seeman, 2002, Atypical antipsychotics: mechanism of action., Can J Psychiatry
Lang et al., 1995, Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis., Clin Neuropharmacol
Kumar B et al., 2018, Lumateperone: a new treatment approach for neuropsychiatric disorders., Drugs Today (Barc)
Kongsamut et al., 1996, Iloperidone binding to human and rat dopamine and 5-HT receptors., Eur. J. Pharmacol.
Hesselink, 2002, Iloperidone (Novartis)., IDrugs
Vinar et al., 1967, Carphenazine in the treatment of schizophrenic psychoses. Controlled clinical trial., Act Nerv Super (Praha)
Platz et al., 1967, Selective drug action related to chronic schizophrenic subtype. (A comparative study of carphenazine, chlorpromazine, and trifluoperazine)., Dis Nerv Syst
Bora, 1968, Comparison of dosage ranges of carphenazine and trifluoperazine in elderly chronic schizophrenics., Dis Nerv Syst
Fuller et al., 1985, Pergolide elevation of MHPG sulphate concentration in rat hypothalamus blocked by spiperone and mimicked by other dopamine agonists., J. Pharm. Pharmacol.
Mehta et al., 2006, Dopaminergic enhancement of cognitive function., Curr. Pharm. Des.
Paturle et al., 1987, Cortical ablation fails to influence striatal dopamine target cell supersensitivity induced by nigrostriatal denervation in the rat., Brain Res.
Huettl et al., 1991, Effects of dopamine receptor agonists and antagonists on catecholamine release in bovine chromaffin cells., J. Pharmacol. Exp. Ther.
Linazasoro et al., Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET., Clin Neuropharmacol
Inoue et al., 1997, Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum., Eur. J. Pharmacol.
Wood et al., 2007, Aripiprazole acts as a selective dopamine D2 receptor partial agonist., Expert Opin Investig Drugs
Hirose et al., 2005, Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist., J. Med. Invest.
Wood et al., 2006, Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties., Eur. J. Pharmacol.
Kim et al., 2006, Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary study., Hum Psychopharmacol
Lawler CP et al., 1999, Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes., Neuropsychopharmacology
Huertas E et al., 2010, The D2 dopamine receptor gene variant C957T affects human fear conditioning and aversive priming., Genes Brain Behav
Hirvonen MM et al., 2009, C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity., Synapse
Betcheva ET et al., 2009, Case-control association study of 59 candidate genes reveals the DRD2 SNP rs6277 (C957T) as the only susceptibility factor for schizophrenia in the Bulgarian population., J Hum Genet
Crettol S et al., 2008, Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment., Prog Neuropsychopharmacol Biol Psychiatry
Allen NC et al., 2008, Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database., Nat Genet
Hoenicka J et al., 2006, C957T DRD2 polymorphism is associated with schizophrenia in Spanish patients., Acta Psychiatr Scand
Hänninen K et al., 2006, Association between the C957T polymorphism of the dopamine D2 receptor gene and schizophrenia., Neurosci Lett
Lawford BR et al., 2005, The C/C genotype of the C957T polymorphism of the dopamine D2 receptor is associated with schizophrenia., Schizophr Res
de Bartolomeis A et al., 2015, Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism., CNS Drugs
Rieck M et al., 2018, Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease., Pharmacogenomics J
Zappia et al., 2005, Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study., Arch. Neurol.
Kovoor et al., 2005, D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways., J. Neurosci.
Mori et al., 2005, Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice., Neurosci. Res.
Onofrj et al., 2008, An expert opinion on safinamide in Parkinson's disease., Expert Opin Investig Drugs
Koller et al., 1998, Mechanism of action of dopaminergic agents in Parkinson's disease., Neurology
Deleu et al., 2002, Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease., Clin Pharmacokinet
Dupre et al., 2007, The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat., Brain Res.
Dahlöf et al., 1998, Pathophysiology and pharmacology of migraine. Is there a place for antiemetics in future treatment strategies?, Cephalalgia
Hammer, Gastroesophageal reflux and prokinetic agents., Neonatal Netw
Chemnitius et al., Indirect parasympathomimetic activity of metoclopramide: reversible inhibition of cholinesterases from human central nervous system and blood., Pharmacol. Res.
See et al., 1996, Subchronic administration of clozapine, but not haloperidol or metoclopramide, decreases dopamine D2 receptor messenger RNA levels in the nucleus accumbens and caudate-putamen in rats., Neuroscience
Kishibayashi et al., 1995, Stimulating effects of KW-5092, a novel gastroprokinetic agent, on the gastric emptying, small intestinal propulsion and colonic propulsion in rats., Jpn. J. Pharmacol.
Harrold et al., 1993, The interaction of ammonium, sulfonium, and sulfide analogues of metoclopramide with the dopamine D2 receptor., J. Med. Chem.
Bartolini A et al., 2011, Analgesic and antineuropathic drugs acting through central cholinergic mechanisms., Recent Pat CNS Drug Discov
Tashiro M et al., 2014, Impact of genetic and non-genetic factors on clinical responses to prochlorperazine in oxycodone-treated cancer patients., Clin Chim Acta
Callan et al., 2008, Prochlorperazine vs. promethazine for headache treatment in the emergency department: a randomized controlled trial., J Emerg Med
Vinson, 2006, Development of a simplified instrument for the diagnosis and grading of akathisia in a cohort of patients receiving prochlorperazine., J Emerg Med
Roberge, 2006, Antiemetic-related dystonic reaction unmasked by removal of a scopolamine transdermal patch., J Emerg Med
Narita et al., 2008, Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer., Eur. J. Pharmacol.
Hamik et al., 1989, Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors., Cancer Chemother. Pharmacol.
Golembiewski et al., 2006, Pharmacological prophylaxis and management of adult postoperative/postdischarge nausea and vomiting., J. Perianesth. Nurs.
Arnt, 1995, Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine., Eur. J. Pharmacol.
Nilsson et al., 1996, Inverse agonism at dopamine D2 receptors. Haloperidol-induced prolactin release from GH4C1 cells transfected with the human D2 receptor is antagonized by R(-)-n-propylnorapomorphine, raclopride, and phenoxybenzamine., Neuropsychopharmacology
Ogren et al., 1984, Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain., Eur. J. Pharmacol.
Reimold et al., 2007, Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol., Psychopharmacology (Berl.)
Ishiwata et al., 2006, A feasibility study of [11C]SA4503-PET for evaluating sigmal receptor occupancy by neuroleptics: the binding of haloperidol to sigma1 and dopamine D2-like receptors., Ann Nucl Med
Leysen et al., 1994, Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity., J Clin Psychiatry
Bustillo et al., 2006, Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels., Neuropsychopharmacology
Osinski et al., 2005, Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets., Pharmacol. Biochem. Behav.
Seeman, 2010, Dopamine D2 receptors as treatment targets in schizophrenia., Clin Schizophr Relat Psychoses
Porcelli S et al., 2016, Possible biomarkers modulating haloperidol efficacy and/or tolerability., Pharmacogenomics
Jönsson EG et al., 1999, Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers., Mol Psychiatry
Pohjalainen T et al., 1998, The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers., Mol Psychiatry
Monteleone P et al., 2009, Management of schizophrenia with obesity, metabolic, and endocrinological disorders., Psychiatr Clin North Am
Hoenicka J et al., 2010, The ANKK1 gene associated with addictions is expressed in astroglial cells and upregulated by apomorphine., Biol Psychiatry
Blum K et al., 1990, Allelic association of human dopamine D2 receptor gene in alcoholism., JAMA
Kraschewski A et al., 2009, Association of the dopamine D2 receptor gene with alcohol dependence: haplotypes and subgroups of alcoholics as key factors for understanding receptor function., Pharmacogenet Genomics
Liu YZ et al., 2009, Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients., Eur J Clin Pharmacol
Doehring A et al., 2009, Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution., Pharmacogenet Genomics
Munafò MR et al., 2009, Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial., Nicotine Tob Res
Le Foll B et al., 2009, Genetics of dopamine receptors and drug addiction: a comprehensive review., Behav Pharmacol
Ikeda M et al., 2008, Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia., Pharmacogenomics
David SP et al., 2008, Genetic variation in the dopamine pathway and smoking cessation., Pharmacogenomics
Thelma B et al., 2008, Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics., Pharmacogenomics
Blum K et al., 1991, Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism., Alcohol
Huang W et al., 2009, Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample., Neuropsychopharmacology
Smith L et al., 2008, Meta-analysis of the association of the Taq1A polymorphism with the risk of alcohol dependency: a HuGE gene-disease association review., Am J Epidemiol
Swan GE et al., 2005, Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR., Pharmacogenomics J
Xu K et al., 2004, Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations., Arch Gen Psychiatry
Neville MJ et al., 2004, Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1., Hum Mutat
Johnstone EC et al., 2004, Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch., Pharmacogenetics
Ritchie T et al., 2003, Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics., Neurochem Res
Schäfer M et al., 2001, Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene., Am J Psychiatry
Suzuki A et al., 2000, The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients., Pharmacogenetics
Mihara K et al., 2000, Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene., Psychopharmacology (Berl)
Kroeze et al., 2003, H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs., Neuropsychopharmacology
Oades et al., 2000, Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy., Behav Pharmacol
Wu et al., 2006, Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients., Acta Pharmacol. Sin.
Roth et al., 1995, D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs., Psychopharmacology (Berl.)
Roth et al., 1994, Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors., J. Pharmacol. Exp. Ther.
Richelson et al., 2000, Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds., Life Sci.
Kapur et al., 2000, A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy., Arch. Gen. Psychiatry
Innis et al., 1992, Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates., Synapse
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Tam et al., 1984, Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes., Proc. Natl. Acad. Sci. U.S.A.
Hallikainen et al., 2003, Ethanol consumption and DRD2 gene TaqI a polymorphism among socially drinking males., Am. J. Med. Genet. A
Comings DE et al., 1994, The dopamine D2 receptor gene: a genetic risk factor in substance abuse., Drug Alcohol Depend
Balldin J et al., 2018, TAQ1A1 Allele of the DRD2 Gene Region Contribute to Shorter Survival Time in Alcohol Dependent Individuals When Controlling for the Influence of Age and Gender. A Follow-up Study of 18 Years., Alcohol Alcohol
Ragia G et al., 2016, Association study of DRD2 A2/A1, DRD3 Ser9Gly, DβH -1021C>T, OPRM1 A118G and GRIK1 rs2832407C>A polymorphisms with alcohol dependence., Drug Metab Pers Ther
Pieters S et al., 2012, The moderating effect of alcohol-specific parental rule-setting on the relation between the dopamine D2 receptor gene (DRD2), the μ-opioid receptor gene (OPRM1) and alcohol use in young adolescents., Alcohol Alcohol
Bolos AM et al., 1990, Population and pedigree studies reveal a lack of association between the dopamine D2 receptor gene and alcoholism., JAMA
Blomqvist O et al., 2000, Family-based study of DRD2 alleles in alcohol and drug dependence., Am J Med Genet
Town T et al., 1999, Association of a functional mu-opioid receptor allele (+118A) with alcohol dependency., Am J Med Genet
Dooley M et al., 1998, Pramipexole. A review of its use in the management of early and advanced Parkinson's disease., Drugs Aging
Chernoloz O et al., 2012, Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain., J Psychiatry Neurosci
Piercey MF, 1998, Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease., Clin Neuropharmacol
Kang SG et al., 2015, DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment., J Clin Psychopharmacol
Rosenzweig et al., 2002, A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers., Hum Psychopharmacol
Horacek et al., 2006, Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia., CNS Drugs
Kalkman et al., 1998, Cataleptogenic effect of subtype selective 5-HT receptor antagonists in the rat., Eur. J. Pharmacol.
Lee et al., 1984, Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain., Psychiatry Res
Hjerde et al., 2005, Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor., Eur J Med Chem
Froimowitz et al., 1997, The incorporation of butyrophenones and related compounds into a pharmacophore for dopamine D2 antagonists., Drug Des Discov
Froimowitz et al., 1993, Biologically active conformers of phenothiazines and thioxanthenes. Further evidence for a ligand model of dopamine D2 receptor antagonists., J. Med. Chem.
Ostadali et al., 2004, The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR., Iran J Allergy Asthma Immunol
Nakamura et al., 2001, Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism., Eur. J. Pharmacol.
Creese I et al., 1996, Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs., J Neuropsychiatry Clin Neurosci
Chokhawala K et al., 2020, Antipsychotic Medications,
Horn AS et al., 1975, Dopamine receptor blockade and the neuroleptics, a crystallographic study., J Pharm Pharmacol
Ali et al., 2006, Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods., Talanta
Høyberg et al., 1993, Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations., Acta Psychiatr Scand
Talvik et al., 2004, A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration., Psychopharmacology (Berl.)
Farde et al., 1989, D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics., Psychopharmacology (Berl.)
Qin et al., 1994, Dopamine receptor blockade increases dopamine D2 receptor and glutamic acid decarboxylase mRNAs in mouse substantia nigra., Eur. J. Pharmacol.
Lidow et al., 1997, Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs., J. Pharmacol. Exp. Ther.
Seeman et al., 1998, Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors., Mol. Psychiatry
Puglisi-Allegra S et al., 1994, Post-training minaprine enhances memory storage in mice: involvement of D1 and D2 dopamine receptors., Psychopharmacology (Berl)
Maeda et al., 2014, Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator., J. Pharmacol. Exp. Ther.
Stahl et al., 2003, The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice., J Clin Psychiatry
Seeger et al., 1995, Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity., J. Pharmacol. Exp. Ther.
Kopecek et al., 2005, Ziprasidone-induced galactorrhea: a case report., Neuro Endocrinol. Lett.
Lucht et al., 2001, Influence of the dopamine D2 receptor (DRD2) exon 8 genotype on efficacy of tiapride and clinical outcome of alcohol withdrawal., Pharmacogenetics
Yamada, 2000, [Disruption of prepulse inhibition of acoustic startle as an animal model for schizophrenia]., Nihon Shinkei Seishin Yakurigaku Zasshi
Yamada et al., 1999, Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats., Biol. Psychiatry
Berlin et al., 2000, Dopaminergic drug response and the genotype (Taq IA polymorphism) of the dopamine D2 receptor., Int. J. Neuropsychopharmacol.
Kim et al., 2001, The localization of dopamine D2 receptor mRNA in the human placenta and the anti-angiogenic effect of apomorphine in the chorioallantoic membrane., Life Sci.
LeWitt PA, 2004, Subcutaneously administered apomorphine: pharmacokinetics and metabolism., Neurology
Pastor et al., 2003, [Cabergoline in the treatment of Parkinson's disease]., Neurologia
Linazasoro et al., Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease., Clin Neuropharmacol
Miyagi et al., 1996, Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents., Biol. Pharm. Bull.
Lombardi et al., 2002, Cabergoline prevents necrotic neuronal death in an in vitro model of oxidative stress., Eur. J. Pharmacol.
Kageyama et al., 2002, A case of macroprolactinoma with subclinical growth hormone production., Endocr. J.
Ichikawa et al., 2001, [Pharmacological effects of cabergoline against parkinsonism]., Nippon Yakurigaku Zasshi
Curran et al., 2004, Cabergoline : a review of its use in the treatment of Parkinson's disease., Drugs
Briani et al., 2004, Thiethylperazine-induced parkinsonism: in vivo demonstration of dopamine D2 receptors blockade., Eur. J. Neurol.
Citrome, 2013, Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability., Expert Opin Drug Metab Toxicol
Kühhorn J et al., 2011, Development of a bivalent dopamine D₂ receptor agonist., J Med Chem
Matera C et al., 2015, Bifunctional compounds targeting both D2 and non-α7 nACh receptors: design, synthesis and pharmacological characterization., Eur J Med Chem
Vangveravong S et al., 2011, Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound., Bioorg Med Chem
Molero A et al., 2015, A solid-phase combinatorial approach for indoloquinolizidine-peptides with high affinity at D(1) and D(2) dopamine receptors., Eur J Med Chem
Tschammer N et al., 2011, Highly potent 5-aminotetrahydropyrazolopyridines: enantioselective dopamine D3 receptor binding, functional selectivity, and analysis of receptor-ligand interactions., J Med Chem
Pagerols M et al., 2017, Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder., Pharmacogenomics J
Regenthal et al., 2005, D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients., Int J Clin Pharmacol Ther
Cohen, Risperidone., Pharmacotherapy
Megens et al., 1994, Survey on the pharmacodynamics of the new antipsychotic risperidone., Psychopharmacology (Berl.)
Remington et al., 2006, A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone., Am J Psychiatry
Yamada et al., 2002, Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy., Synapse
Scatton et al., 2001, The preclinical pharmacologic profile of tiapride., Eur. Psychiatry
Pache et al., 2003, Buspirone differentially modifies short-term memory function in a combined delayed matching/non-matching to position task., Eur. J. Pharmacol.
Nader et al., 1993, Interactions of buspirone or gepirone with nicotine on schedule-controlled behavior of pigeons., Behav Pharmacol
Malt et al., 2003, Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls., J Affect Disord
Boido et al., 2001, Synthesis and pharmacological evaluation of aryl/heteroaryl piperazinyl alkyl benzotriazoles as ligands for some serotonin and dopamine receptor subtypes., Farmaco
Fernández-Pérez et al., 2005, Co-administration of fluoxetine and WAY100635 improves short-term memory function., Eur. J. Pharmacol.
Cusack et al., 1994, Binding of antidepressants to human brain receptors: focus on newer generation compounds., Psychopharmacology (Berl.)
Murphy et al., 1999, Inhibition of luteinizing hormone secretion by delta9-tetrahydrocannabinol in the ovariectomized rat: effect of pretreatment with neurotransmitter or neuropeptide receptor antagonists., Steroids
Freedman et al., 1994, Expression and pharmacological characterization of the human D3 dopamine receptor., J. Pharmacol. Exp. Ther.
Zarrindast et al., 1994, On the mechanisms by which theophylline changes core body temperature in mice., Eur. J. Pharmacol.
Muscat et al., 1990, Dopaminergic mechanism of imipramine action in an animal model of depression., Biol. Psychiatry
Silva et al., 2003, Pimozide injections into the Nucleus accumbens disrupt maternal behaviour in lactating rats., Pharmacol. Toxicol.
Lahti et al., 1993, Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications., Eur. J. Pharmacol.
Seeman et al., 1976, Antipsychotic drug doses and neuroleptic/dopamine receptors., Nature
Schmidt et al., 1991, Investigation of striatal dopamine D2 receptor acquisition following prenatal neuroleptic exposure., Psychiatry Res
Cahir et al., 2005, Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat., Eur Neuropsychopharmacol
Schulze M et al., 2009, Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities?, Bioorg Med Chem
Lane et al., 2004, Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function., Int. J. Neuropsychopharmacol.
Fenton et al., 2005, Risperidone: a review of its use in the treatment of bipolar mania., CNS Drugs
Catafau et al., 2006, Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response., Psychiatry Res
Corena-McLeod M, 2015, Comparative Pharmacology of Risperidone and Paliperidone., Drugs R D
von Coburg et al., 2009, Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics., Bioorg. Med. Chem. Lett.
Fux et al., 1991, A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia., Isr J Psychiatry Relat Sci
Burstein et al., 2005, Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist., J. Pharmacol. Exp. Ther.
Choi et al., 2004, Synthesis, receptor binding and functional studies of mesoridazine stereoisomers., Bioorg. Med. Chem. Lett.
Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
Nyberg et al., 1995, Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans., Int Clin Psychopharmacol
Gareri et al., 2003, Conventional and atypical antipsychotics in the elderly : a review., Clin Drug Investig
Lublin et al., 1991, Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia., Eur Neuropsychopharmacol
Seeman, 1990, Atypical neuroleptics: role of multiple receptors, endogenous dopamine, and receptor linkage., Acta Psychiatr Scand Suppl
Carey et al., 1997, Discriminative-stimulus effects of clozapine in squirrel monkeys: comparison with conventional and novel antipsychotic drugs., Psychopharmacology (Berl.)
Assié et al., 1993, Biphasic displacement of [3H]YM-09151-2 binding in the rat brain by thioridazine, risperidone and clozapine, but not by other antipsychotics., Eur. J. Pharmacol.
Barth et al., 2006, Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer., Life Sci.
Dimpfel et al., 1992, Different neuroleptics show common dose and time dependent effects in quantitative field potential analysis in freely moving rats., Psychopharmacology (Berl.)
Nasu et al., 2000, Quantitative prediction of catalepsy induced by amoxapine, cinnarizine and cyclophosphamide in mice., Biopharm Drug Dispos
Wei et al., 1990, [Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration]., Yao Xue Xue Bao
Bartoszyk GD et al., 2004, Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile., J Neural Transm (Vienna)
George et al., 2013, Newer antipsychotics and upcoming molecules for schizophrenia., Eur. J. Clin. Pharmacol.
Schotte et al., 1996, Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding., Psychopharmacology (Berl.)
Wang, 2002, Inhibition of glutamate release by fluspirilene in cerebrocortical nerve terminals (synaptosomes)., Synapse
Cannon JG et al., 1986, p-Dimethoxy-substituted trans-octahydrobenzo[f]- and -[g]quinolines: synthesis and assessment of dopaminergic agonist effects., J Med Chem
Mouly S et al., 2015, Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity., Br J Clin Pharmacol
Levran O et al., 2013, Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction., Pharmacogenomics
Hung CC et al., 2011, Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients., Pharmacogenomics
Green et al., 2004, Focus on levomepromazine., Curr Med Res Opin
Dahl et al., 1986, Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding., Biochem. Pharmacol.
Larson, 2003, The effect of antiemetics on pupillary reflex dilation during epidural/general anesthesia., Anesth. Analg.
Gao et al., 2010, The effect of dopamine on pain-related neurons in the parafascicular nucleus of rats., J Neural Transm (Vienna)
Grip et al., 1992, Histopathology and evaluation of potentiation of morphine-induced antinociception by intrathecal droperidol in the rat., Acta Anaesthesiol Scand
Holtmann et al., 2006, A placebo-controlled trial of itopride in functional dyspepsia., N. Engl. J. Med.
Choung et al., 2007, A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers., Neurogastroenterol. Motil.
Deeks ED et al., 2010, Blonanserin: a review of its use in the management of schizophrenia., CNS Drugs
Kim DH et al., 2009, Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia., Neurotherapeutics
Adolph O et al., 2012, Promethazine inhibits NMDA-induced currents - new pharmacological aspects of an old drug., Neuropharmacology
Strange PG, 2008, Antipsychotic drug action: antagonism, inverse agonism or partial agonism., Trends Pharmacol Sci
Rouge-Pont et al., 2002, Changes in extracellular dopamine induced by morphine and cocaine: crucial control by D2 receptors., J. Neurosci.
Lahlou, 1999, Cardiovascular responses to intrathecal dopamine receptor agonists in conscious DOCA-salt hypertensive rats., Fundam Clin Pharmacol
Lahlou et al., 2003, Blunted central bromocriptine-induced tachycardia in conscious, malnourished rats., Pharmacol. Toxicol.
Stefaneanu et al., 2001, Dopamine D2 receptor gene expression in human adenohypophysial adenomas., Endocrine
Lahlou et al., 2000, Effects of long-term pretreatment with isoproterenol on bromocriptine-induced tachycardia in conscious rats., Can. J. Physiol. Pharmacol.
Cinciripini P et al., 2004, The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood., Nicotine Tob Res
Shultz et al., 1987, Dopaminergic stimulation of cAMP accumulation in cultured rat mesangial cells., Am. J. Physiol.
Dziedzicka-Wasylewska et al., 1996, The effect of prolonged administration of lithium on the level of dopamine D2 receptor mRNA in the rat striatum and nucleus accumbens., Acta Neurobiol Exp (Wars)
Masellis M et al., 2016, Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study., Brain
Cargnin S et al., 2014, Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache., Eur J Clin Pharmacol
Langlois X et al., 2012, Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia., J Pharmacol Exp Ther
Spellicy CJ et al., 2013, ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse., Pharmacogenet Genomics

NEMONAPRIDE DRD2

Interaction Score: 7.49

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9918131 9858029 28673279 20194480 17105675 16513877 15694263 10395223 9672901 19944883 19853839 1969501 19603545 19396436 19373123 19273465 19179847 18926547 18855532 18781857 18781856 1839129 18354387 18180754 18086475 17989061 17767146 15830237 15492764 15286066 15184239 15146457 15077009 12587665 11505224 11329406 10862524 10823405

Sources:
PharmGKB TTD
CABERGOLINE DRD2

Interaction Score: 5.25

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Dopamine D2 receptor agonist

PMIDs:
18808942 12721865 18303487 8951172 12464354 12008749 11752352 11436517 15341508

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD
PERGOLIDE DRD2

Interaction Score: 1.62

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
18808942 2860228 16842172 11752352 3828803 1674528 18691132 10516878 10641988

Sources:
TdgClinicalTrial TEND PharmGKB TTD
JNJ-37822681 DRD2

Interaction Score: 1.12

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name JNJ-37822681

Novel drug target Established target

PMIDs:
22490380

Sources:
TdgClinicalTrial TTD
PRIDOPIDINE DRD2

Interaction Score: 1.12

Interaction Types & Directionality:

modulator

Interaction Info:

Novel drug target Established target

Trial Name pridopidine, ACR-16,Huntexil

Mechanism of Interaction Dopamine D2 receptor modulator

PMIDs:
None found

Sources:
TdgClinicalTrial ChemblInteractions TTD
PRAMIPEXOLE DRD2

Interaction Score: 1.12

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name Mirapex

Novel drug target Established target

PMIDs:
18691132 10641988 11752352 9638397 22023785 9617505

Sources:
TdgClinicalTrial TEND TTD
ARIPIPRAZOLE DRD2

Interaction Score: 1.12

Interaction Types & Directionality:

partial agonist (activating)

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Trial Name Abilify

Novel drug target Established target

Mechanism of Interaction Dopamine D2 receptor partial agonist

PMIDs:
9083792 17501690 11752352 16366516 16925992 16981227 9918131 28673279 20194480 10327430 991813 9858029 9713903 19900188 19582781 19158809 18926547 18687376 18583979 17105675 17087792 16973280 16513877 16123753 15830237 15694263 15567074 14610521 11920858 11505224 26346901

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD
ROPINIROLE DRD2

Interaction Score: 1.12

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name JZP-7

Novel drug target Established target

Trial Name ReQuip

PMIDs:
18808942 1683559 10446316 17573046 11752352 18691132 10641988 19557097

Sources:
TdgClinicalTrial TEND PharmGKB TTD
BROMPERIDOL DRD2

Interaction Score: 1.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9918131 9858029 28673279 20194480 18926547 17105675 16513877 15830237 15694263 11505224

Sources:
PharmGKB
MOLINDONE DRD2

Interaction Score: 1.0

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
9353417 9577836 17016423 9342550 11752352

Sources:
TdgClinicalTrial TEND TTD
ACETOPHENAZINE DRD2

Interaction Score: 1.0

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
11752352 11873706 17016423 17139284 6147851

Sources:
TdgClinicalTrial TEND TTD
THIOTHIXENE DRD2

Interaction Score: 0.84

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor antagonist

Direct Interaction yes

PMIDs:
11103886 16867246 20643630 15694263 11873706 3039860 11752352

Sources:
ChemblInteractions TTD
5-OH-DPAT DRD2

Interaction Score: 0.75

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3783613

Sources:
DTC
BUPROPION DRD2

Interaction Score: 0.71

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16123753 10395223 9672901 19944883 19853839 1969501 19603545 19396436 19373123 19273465 19179847 18926547 18855532 18781857 18781856 1839129 18354387 18180754 18086475 17989061 17767146 15830237 15492764 15286066 15184239 15146457 15077009 12587665 11329406 10862524 10823405

Sources:
PharmGKB
LOXAPINE DRD2

Interaction Score: 0.69

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name AZ-004

Mechanism of Interaction D2-like dopamine receptor antagonist

PMIDs:
9570468 6239298 15694653 8665533 9342550 11752352 8101879

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
FLUPENTIXOL DRD2

Interaction Score: 0.67

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
7498321 8797192 6149133 11873706 11752352 1674528 17111172 21421319

Sources:
DTC
CARPHENAZINE DRD2

Interaction Score: 0.66

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
4889058 4861216 11752352 4887393

Sources:
TdgClinicalTrial TEND TTD
LISURIDE DRD2

Interaction Score: 0.62

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
18691132 11752352

Sources:
TdgClinicalTrial TEND TTD
DOMPERIDONE DRD2

Interaction Score: 0.6

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
12010185 15894081 1683559 18970411 11752352

Sources:
TdgClinicalTrial TEND TTD
MESORIDAZINE DRD2

Interaction Score: 0.56

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
16135699 15357957 11752352

Sources:
TdgClinicalTrial TEND TTD
ZUCLOPENTHIXOL DRD2

Interaction Score: 0.52

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
8748043 17535043 11752352 1822319

Sources:
TdgClinicalTrial TEND TTD
DROPERIDOL DRD2

Interaction Score: 0.5

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor antagonist

Direct Interaction yes

Trial Name -

PMIDs:
14633536 20358234 1549935 2527092

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
QUINPIROLE DRD2

Interaction Score: 0.45

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

PMIDs:
21999579 26164842 21536445 25969169 21388142

Sources:
DTC
RISPERIDONE DRD2

Interaction Score: 0.44

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dopamine D2 receptor antagonist

Trial Name -

PMIDs:
16730699 15140279 16513859 15907153 11752352 17059881 11132243 9918131 28673279 26872113 23859574 23851570 20714340 20375926 20194480 18579277 10395223 991813 9858029 9713903 9672901 19944883 19853839 1969501 19603545 19396436 19373123 19273465 19179847 18926547 18855532 18781857 18781856 1839129 18354387 18180754 18086475 17989061 17767146 17105675 16513877 16123753 15830237 15694263 15492764 15286066 15184239 15146457 15077009 14610521 12587665 11920858 11505224 11329406 10862524 10823405 21421319 25943458

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD
CHLORPROTHIXENE DRD2

Interaction Score: 0.43

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dopamine D2 receptor antagonist

Trial Name -

PMIDs:
19091563 8101879 1830565 11752352

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
PALIPERIDONE DRD2

Interaction Score: 0.42

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name paliperidone ER, paliperidone palmitate

Mechanism of Interaction Dopamine D2 receptor antagonist

PMIDs:
16119512 7524043 7531353 16513859 11752352 11132243 12211096

Sources:
TdgClinicalTrial ChemblInteractions TEND
DOCARPAMINE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
QUINAGOLIDE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

PMIDs:
None found

Sources:
TTD
SERIDOPIDINE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

modulator

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor modulator

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
THIETHYLPERAZINE MALEATE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
BL-1020 DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
APLINDORE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name Aplindore, DAB-452

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
RASAGILINE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27190009

Sources:
PharmGKB
BENZQUINAMIDE HYDROCHLORIDE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

modulator

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dopamine D2 receptor modulator

PMIDs:
None found

Sources:
ChemblInteractions
DENOPAMINE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
DOPEXAMINE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
ACETOPHENAZINE MALEATE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
BLONANSERIN DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
20030420

Sources:
TTD
ITOPRIDE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name itopride,Itax

Novel drug target Established target

PMIDs:
16495395 17300287

Sources:
TdgClinicalTrial
APLINDORE FUMARATE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

partial agonist (activating)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor partial agonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
SARIZOTAN DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

partial agonist (activating)

Interaction Info:

PMIDs:
14767715

Sources:
TTD
STEPHOLIDINE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19744859

Sources:
DTC
BUSPIRONE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
14522358 11224194 12781354 11421254 16214127

Sources:
TdgClinicalTrial TEND
TIAPRIDE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

PMIDs:
11520476

Sources:
TTD
ORDOPIDINE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

modulator

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dopamine D2 receptor modulator

PMIDs:
None found

Sources:
ChemblInteractions
FLUPHENAZINE ENANTHATE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CARIPRAZINE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

partial agonist (activating)

agonist (activating)

Interaction Info:

Trial Name cariprazine, RGH-188

Novel drug target Established target

PMIDs:
23320989

Sources:
TdgClinicalTrial TTD
CARMOXIROLE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
FLUPHENAZINE DECANOATE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dopamine D2 receptor antagonist

PMIDs:
None found

Sources:
ChemblInteractions
TRIFLUPROMAZINE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Dopamine D2 receptor antagonist

PMIDs:
17016423 17139284 9081563 30137788 239169

Sources:
TdgClinicalTrial ChemblInteractions TEND
SUMANIROLE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

PMIDs:
None found

Sources:
TTD
SULPIRIDE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
12010185 11752352 7518029 22632094

Sources:
DTC TdgClinicalTrial TEND TTD
CHLORPROMAZINE DRD2

Interaction Score: 0.36

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor antagonist

Direct Interaction yes

PMIDs:
11103886 16867246 20643630 15694263 8524985 11873706 11752352 7908055 9918131 9858029 28673279 20194480 18926547 17105675 16513877 15830237 11505224

Sources:
ChemblInteractions PharmGKB TTD
METOCLOPRAMIDE DRD2

Interaction Score: 0.34

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name MT 100

Trial Name metoclopramide,Emitasol, Pramidin

Trial Name metoclopramide HCl,Metzoliv ODT

PMIDs:
9876882 15835479 8981558 8730709 7745844 8230103 11752352 21585331

Sources:
TdgClinicalTrial TEND TTD
AMISULPRIDE DRD2

Interaction Score: 0.33

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name amisulpride,Solian

Novel drug target Established target

Trial Name APD421

PMIDs:
25679126 12404702 11873706 16696579

Sources:
TdgClinicalTrial TEND PharmGKB TTD
APOMORPHINE DRD2

Interaction Score: 0.32

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name apomorphine HCl,Uprima, Ixense

Novel drug target Established target

Trial Name apomorphine hydrochloride,Apokyn, APO-go

PMIDs:
11692072 11215397 10494453 11343576 11752352 11212866 18691132 10641988 15037665

Sources:
TdgClinicalTrial TEND TTD
MINAPRINE DRD2

Interaction Score: 0.31

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
17016423 17139284 7862862

Sources:
TdgClinicalTrial TEND
REMOXIPRIDE DRD2

Interaction Score: 0.31

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
11873706 8665533 11752352

Sources:
TdgClinicalTrial TEND
BREXPIPRAZOLE DRD2

Interaction Score: 0.3

Interaction Types & Directionality:

partial agonist (activating)

agonist (activating)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor partial agonist

Direct Interaction yes

Novel drug target Established target

PMIDs:
24947465

Sources:
TdgClinicalTrial ChemblInteractions TTD
ROTIGOTINE DRD2

Interaction Score: 0.3

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name Neupro

Novel drug target Established target

Mechanism of Interaction D2-like dopamine receptor agonist

PMIDs:
18691132

Sources:
TdgClinicalTrial ChemblInteractions TEND
HALOPERIDOL DRD2

Interaction Score: 0.29

Interaction Types & Directionality:

inverse agonist (inhibitory)

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction D2-like dopamine receptor inverse agonist

Trial Name -

PMIDs:
17134027 7520908 16132064 16730699 15894081 20643630 17316700 11752352 12887421 21421319 27023437 10395223 9672901 19944883 19853839 1969501 19603545 19396436 19373123 19273465 19179847 18926547 18855532 18781857 18781856 1839129 18354387 18180754 18086475 17989061 17767146 15830237 15492764 15286066 15184239 15146457 15077009 12587665 11329406 10862524 10823405 12629531

Sources:
DTC TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB TTD
BROMOCRIPTINE DRD2

Interaction Score: 0.26

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name bromocriptine mesylate,Cycloset, Ergoset

Novel drug target Established target

PMIDs:
12010185 10626749 11752352 12753422 11444429 10721819 18691132 10641988

Sources:
TdgClinicalTrial TEND TTD
OCAPERIDONE DRD2

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10592235

Sources:
TTD
PERPHENAZINE DRD2

Interaction Score: 0.25

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

Direct Interaction yes

PMIDs:
7508675 15007534 2573104 11873706 11752352 7828655

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
BIFEPRUNOX DRD2

Interaction Score: 0.25

Interaction Types & Directionality:

partial agonist (activating)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor partial agonist

Direct Interaction yes

Trial Name bifeprunox, DU127090

PMIDs:
17393144 17659474

Sources:
TdgClinicalTrial ChemblInteractions
CLOZAPINE DRD2

Interaction Score: 0.24

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

Mechanism of Interaction Dopamine D2 receptor antagonist

PMIDs:
12887421 9918131 28673279 26872113 23859574 23851570 20714340 20375926 20194480 18579277 18180754 18086475 17767146 11505224 991813 9858029 9713903 18926547 17105675 16513877 16123753 15830237 15694263 14610521 11920858 15286066 14575800 12769622 11752352 15781964 16040180 21421319

Sources:
DTC TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB
SERTINDOLE DRD2

Interaction Score: 0.24

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name Serdolect

Novel drug target Established target

PMIDs:
19506838 20856607 11752352 16925508 18293356

Sources:
TdgClinicalTrial TEND
LURASIDONE DRD2

Interaction Score: 0.22

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name lurasidone, SM-13496,Latuda

Novel drug target Established target

PMIDs:
23545936

Sources:
TdgClinicalTrial TEND
THIORIDAZINE DRD2

Interaction Score: 0.22

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction D2-like dopamine receptor antagonist

PMIDs:
1978482 9292626 7689973 16434058 1352051

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
FLUPHENAZINE DRD2

Interaction Score: 0.22

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
11873706 7508675 11752352 7828655

Sources:
TdgClinicalTrial TEND
LUMATEPERONE DRD2

Interaction Score: 0.22

Interaction Types & Directionality:

partial agonist (activating)

antagonist (inhibitory)

Interaction Info:

Trial Name ITI-007, ITI-722

Novel drug target Established target

Mechanism of Interaction Dopamine D2 receptor partial agonist

PMIDs:
30596390

Sources:
TdgClinicalTrial ChemblInteractions
OLANZAPINE DRD2

Interaction Score: 0.22

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor antagonist

Direct Interaction yes

Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

PMIDs:
9918131 28673279 26872113 25563748 23859574 23851570 22967772 21095016 20714340 20375926 20194480 18579277 18180754 18086475 17767146 11505224 991813 9858029 9713903 18926547 17105675 16513877 16123753 15830237 15694263 14610521 11920858 17067304 14575800 16730699 17316700 17092971 11752352 17848919 25032030

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD
PROCHLORPERAZINE DRD2

Interaction Score: 0.22

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name AZ-001, Staccato prochlorperazine

Novel drug target Established target

Trial Name buccal prochlorperazine maleate,Emezine

PMIDs:
24360851 18534808 17044574 16677982 11752352 18955042 2527092 17169748

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD
THIETHYLPERAZINE DRD2

Interaction Score: 0.2

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
15469457 17016423 17139284

Sources:
TdgClinicalTrial TEND TTD
SB-773812 DRD2

Interaction Score: 0.19

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
UMESPIRONE DRD2

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
MOLINDONE HYDROCHLORIDE DRD2

Interaction Score: 0.19

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
TALIPEXOLE DRD2

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
RISPERDAL DRD2

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name Risperdal

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
PERAZINE DRD2

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
PROPIOMAZINE DRD2

Interaction Score: 0.19

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
17016423 17139284 19110200 22507664 18471899

Sources:
TdgClinicalTrial TEND
PROCHLORPERAZINE MALEATE DRD2

Interaction Score: 0.19

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
MESORIDAZINE BESYLATE DRD2

Interaction Score: 0.19

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
TOLAZOLINE DRD2

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
CARIPRAZINE HYDROCHLORIDE DRD2

Interaction Score: 0.19

Interaction Types & Directionality:

modulator

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dopamine D2 receptor modulator

PMIDs:
None found

Sources:
ChemblInteractions
ABAPERIDONE DRD2

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
NAPHAZOLINE DRD2

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
BEVANTOLOL DRD2

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
LURASIDONE HYDROCHLORIDE DRD2

Interaction Score: 0.19

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dopamine D2 receptor antagonist

PMIDs:
None found

Sources:
ChemblInteractions
ZIPRASIDONE DRD2

Interaction Score: 0.19

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name ziprasidone HCl, ziprasidone mesylate,Geodon, Zeldox

Novel drug target Established target

PMIDs:
14728084 11873706 7562537 11752352 17848919 15726024

Sources:
TdgClinicalTrial TEND TTD
MEPHENTERMINE DRD2

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
ASENAPINE MALEATE DRD2

Interaction Score: 0.19

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dopamine D2 receptor antagonist

PMIDs:
None found

Sources:
ChemblInteractions
FLUSPIRILENE DRD2

Interaction Score: 0.18

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
8935801 11752352 17139284 11842444 17016423

Sources:
TdgClinicalTrial TEND TTD
PIMOZIDE DRD2

Interaction Score: 0.17

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Dopamine receptor antagonist

Direct Interaction yes

Novel drug target Established target

PMIDs:
7855217 10503726 8301582 8082693 2378927 11873706 12828573 11752352

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
PARDOPRUNOX DRD2

Interaction Score: 0.16

Interaction Types & Directionality:

partial agonist (activating)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dopamine receptors; D2 & D3 partial agonist

Trial Name pardoprunox, SLV 308

PMIDs:
None found

Sources:
TdgClinicalTrial ChemblInteractions TTD
ANIRACETAM DRD2

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11412837

Sources:
TTD
ILOPERIDONE DRD2

Interaction Score: 0.15

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor antagonist

Direct Interaction yes

Novel drug target Established target

PMIDs:
8997630 12861482

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
QUETIAPINE DRD2

Interaction Score: 0.14

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name Seroquel

Novel drug target Established target

PMIDs:
21421319 11132243 11873706 17848919 11752352 10839333

Sources:
DTC TdgClinicalTrial TEND TTD
LEVOMEPROMAZINE DRD2

Interaction Score: 0.13

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor antagonist

Direct Interaction yes

PMIDs:
10592235 15701205 2870716

Sources:
ChemblInteractions TTD
PROMAZINE DRD2

Interaction Score: 0.13

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
17016423 17139284 19110200 18471899

Sources:
TdgClinicalTrial TEND
ZIPRASIDONE MESYLATE DRD2

Interaction Score: 0.12

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
QUETIAPINE FUMARATE DRD2

Interaction Score: 0.12

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
ARIPIPRAZOLE LAUROXIL DRD2

Interaction Score: 0.12

Interaction Types & Directionality:

partial agonist (activating)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor partial agonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
DEXPRAMIPEXOLE DRD2

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name dexpramipexole, KNS-760704

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
PRAMIPEXOLE DIHYDROCHLORIDE DRD2

Interaction Score: 0.12

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor agonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
THIOTHIXENE HYDROCHLORIDE DRD2

Interaction Score: 0.12

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dopamine D2 receptor antagonist

PMIDs:
None found

Sources:
ChemblInteractions
EPHEDRINE DRD2

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
METOCLOPRAMIDE HYDROCHLORIDE DRD2

Interaction Score: 0.12

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PIPERACETAZINE DRD2

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
APOMORPHINE HYDROCHLORIDE DRD2

Interaction Score: 0.12

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor agonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
ERGONOVINE DRD2

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
TRIFLUOPERAZINE DRD2

Interaction Score: 0.12

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
8102973 945467 1676523 11873706 15695070 11752352

Sources:
TdgClinicalTrial TEND
CARPHENAZINE MALEATE DRD2

Interaction Score: 0.12

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dopamine D2 receptor antagonist

PMIDs:
None found

Sources:
ChemblInteractions
ROXINDOLE DRD2

Interaction Score: 0.12

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
TTD
ZIPRASIDONE HYDROCHLORIDE DRD2

Interaction Score: 0.12

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
LEVODOPA DRD2

Interaction Score: 0.12

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name DM-1992

Novel drug target Established target

Trial Name entacapone/levodopa/carbidopa,Stalevo

PMIDs:
27779245 15824260 15728856 15710490 18549347 9633680 11978145 17553470

Sources:
TdgClinicalTrial TEND PharmGKB TTD
DIHYDREXIDINE DRD2

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19744859

Sources:
DTC
ASENAPINE DRD2

Interaction Score: 0.1

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name Asenapine

Novel drug target Established target

PMIDs:
18308814 21658377 21655346

Sources:
TdgClinicalTrial TEND
HALOPERIDOL DECANOATE DRD2

Interaction Score: 0.09

Interaction Types & Directionality:

inverse agonist (inhibitory)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor inverse agonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
SARIZOTAN HYDROCHLORIDE DRD2

Interaction Score: 0.09

Interaction Types & Directionality:

partial agonist (activating)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor partial agonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
ZICRONAPINE DRD2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
E-FLUPENTIXOL DRD2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TEND
PHENYLTOLOXAMINE DRD2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
HALOPERIDOL LACTATE DRD2

Interaction Score: 0.09

Interaction Types & Directionality:

inverse agonist (inhibitory)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor inverse agonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
ROPINIROLE HYDROCHLORIDE DRD2

Interaction Score: 0.09

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor agonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
DAPIPRAZOLE DRD2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
METHADONE DRD2

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25556837 23651024 21902500 19373123 18687376

Sources:
PharmGKB
AMOXAPINE DRD2

Interaction Score: 0.08

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Dopamine receptor antagonist

Direct Interaction yes

PMIDs:
11180191 1966571

Sources:
ChemblInteractions
DIHYDROERGOTAMINE DRD2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
OLANZAPINE PAMOATE DRD2

Interaction Score: 0.07

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
ETILEVODOPA DRD2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name etilevodopa, TV-1203

PMIDs:
None found

Sources:
TdgClinicalTrial
LOXAPINE HYDROCHLORIDE DRD2

Interaction Score: 0.07

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
ONC-201 DRD2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
TRIFLUPROMAZINE HYDROCHLORIDE DRD2

Interaction Score: 0.06

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
LOXAPINE SUCCINATE DRD2

Interaction Score: 0.06

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
DOPAMINE DRD2

Interaction Score: 0.06

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

PMIDs:
17301410 11752352

Sources:
TTD
AMPHETAMINE DRD2

Interaction Score: 0.06

Interaction Types & Directionality:

binder

Interaction Info:

PMIDs:
1532675

Sources:
PharmGKB
ALCOHOL DRD2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12749054 8033754 29236941 27447243 22798433 1979357 1969501 1839129 17989061 11054774 10490697

Sources:
NCI PharmGKB
FLUPHENAZINE HYDROCHLORIDE DRD2

Interaction Score: 0.05

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
SUMATRIPTAN DRD2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25096645

Sources:
PharmGKB
BROMOCRIPTINE MESYLATE DRD2

Interaction Score: 0.05

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor agonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PERGOLIDE MESYLATE DRD2

Interaction Score: 0.05

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dopamine receptor agonist

PMIDs:
None found

Sources:
ChemblInteractions
MELEVODOPA DRD2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name V-1512, CHF-1512,Levomet Complex, Sirio

PMIDs:
None found

Sources:
TdgClinicalTrial
TRIMIPRAMINE MALEATE DRD2

Interaction Score: 0.05

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dopamine D2 receptor antagonist

PMIDs:
None found

Sources:
ChemblInteractions
METARAMINOL DRD2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
PHENOXYBENZAMINE DRD2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
PROMAZINE HYDROCHLORIDE DRD2

Interaction Score: 0.05

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PROCHLORPERAZINE EDISYLATE DRD2

Interaction Score: 0.05

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
THIETHYLPERAZINE MALATE DRD2

Interaction Score: 0.05

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PHENTOLAMINE DRD2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
TRIFLUOPERAZINE HYDROCHLORIDE DRD2

Interaction Score: 0.03

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
ERGOLOID MESYLATES DRD2

Interaction Score: 0.03

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Dopamine receptor agonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
DIACETYLMORPHINE DRD2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PHENYLEPHRINE DRD2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
THIORIDAZINE HYDROCHLORIDE DRD2

Interaction Score: 0.02

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction D2-like dopamine receptor antagonist

PMIDs:
None found

Sources:
ChemblInteractions
MORPHINE DRD2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11943831

Sources:
NCI
NICOTINE DRD2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16123753 15203796

Sources:
PharmGKB
PSEUDOEPHEDRINE DRD2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
CHLORPROMAZINE HYDROCHLORIDE DRD2

Interaction Score: 0.02

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
DISULFIRAM DRD2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23635803

Sources:
PharmGKB
COCAINE DRD2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
METHYLPHENIDATE DRD2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26810137

Sources:
PharmGKB
LITHIUM DRD2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8787189

Sources:
NCI
METHAMPHETAMINE DRD2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
METHYLDOPA DRD2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD

Ensembl: ENSG00000149295
- Version: 101_38
Alternate Names:

DRD2 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TEND: P14416
- Version: 01-August-2011
Alternate Names:

1813 Entrez Gene Id

DRD2 Gene Symbol

ENSG00000149295 Ensembl Gene Id

Gene Info:

Target Main Class Receptors

Target Subclass Rhodopsin

Transmembrane Helix Count 7

Publications:
HopkinsGroom: P14416
- Version: 11-September-2012
Alternate Names:

1813 Entrez Gene Id

ENSG00000149295 Ensembl Gene Id

D(2) DOPAMINE RECEPTOR Uniprot Protein Name

Gene Info:

Interpro Name GPCR, rhodopsin-like, 7TM

Interpro Short Name 7TM_GPCR_Rhodpsn

Human Readable Name DRUGGABLE GENOME

Gene Categories:

G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME

Publications:
RussLampel: ENSG00000149295
- Version: 26-July-2011
Alternate Names:

ENSG00000149295 Ensembl Gene Id

DRD2 Display Id

D(2) DOPAMINE RECEPTOR (DOPAMINE D2 RECEPTOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P14416] Description

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:
TdgClinicalTrial: P14416
- Version: January-2014
Alternate Names:

DRD2 Gene Symbol

Gene Info:

Target Class Receptors

Target Subclass GPCR

Target Subclass Rhodopsin

Publications:

PharmGKB: DRD2

Version: 18-August-2020

Alternate Names:

PA27478 PharmGKB ID

Gene Info:

Publications:

Rieck M et al., 2018, Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease., Pharmacogenomics J

Li T et al., 1998, Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia., Schizophr Res

Müller DJ et al., 2012, Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain., Pharmacogenomics J

TTD: Dopamine D2 receptor

Version: 2020.06.01

Alternate Names:

D2R TTD Gene Abbreviation

T67162 TTD Target ID

Gene Info:

Publications:

Guo JD et al., 2009, Bi-directional modulation of bed nucleus of stria terminalis neurons by 5-HT: molecular expression and functional properties of excitatory 5-HT receptor subtypes., Neuroscience

NCI: DRD2

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Lipska et al., 2003, Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs., Eur. J. Neurosci.

Brené et al., 1990, Expression of dopamine D2 receptor and choline acetyltransferase mRNA in the dopamine deafferented rat caudate-putamen., Exp Brain Res

Hallikainen et al., 2003, Ethanol consumption and DRD2 gene TaqI a polymorphism among socially drinking males., Am. J. Med. Genet. A

DTC: DRD2

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

Vangveravong S et al., 2011, Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound., Bioorg Med Chem

Tschammer N et al., 2011, Highly potent 5-aminotetrahydropyrazolopyridines: enantioselective dopamine D3 receptor binding, functional selectivity, and analysis of receptor-ligand interactions., J Med Chem

Matera C et al., 2015, Bifunctional compounds targeting both D2 and non-α7 nACh receptors: design, synthesis and pharmacological characterization., Eur J Med Chem

ChemblInteractions: DRD2
- Version: chembl_23
Alternate Names:

DRD2 GENE_SYMBOL

D(2) dopamine receptor UNIPROT

Dopamine D2 receptor UNIPROT

Gene Info:

Publications:
HingoraniCasas: ENSG00000149295
- Version: 31-May-2017
Alternate Names:

ENSG00000149295 Gene Symbol

DRD2 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
dGene: DRD2
- Version: 27-Jun-2013
Alternate Names:

1813 Gene ID

D2DR dGene Synonym

D2R dGene Synonym

Gene Info:

Gene Categories:

G PROTEIN COUPLED RECEPTOR

Publications:
GO: DRD2
- Version: 01-February-2022
Alternate Names:

Gene Info:

Gene Categories:

G PROTEIN COUPLED RECEPTOR

Publications:

Trial Name	-
Novel drug target	Established target
Mechanism of Interaction	Dopamine D2 receptor agonist

Trial Name	Abilify
Novel drug target	Established target
Mechanism of Interaction	Dopamine D2 receptor partial agonist

Trial Name	JZP-7
Novel drug target	Established target
Trial Name	ReQuip

Mechanism of Interaction	Dopamine D2 receptor antagonist
Direct Interaction	yes

Mechanism of Interaction	D2-like dopamine receptor antagonist
Direct Interaction	yes
Trial Name	-

Mechanism of Interaction	Dopamine D2 receptor modulator
Direct Interaction	yes

Trial Name	Aplindore, DAB-452
Novel drug target	Established target

Trial Name	cariprazine, RGH-188
Novel drug target	Established target

Trial Name	MT 100
Trial Name	metoclopramide,Emitasol, Pramidin
Trial Name	metoclopramide HCl,Metzoliv ODT

Trial Name	amisulpride,Solian
Novel drug target	Established target
Trial Name	APD421

Trial Name	apomorphine HCl,Uprima, Ixense
Novel drug target	Established target
Trial Name	apomorphine hydrochloride,Apokyn, APO-go

Trial Name	Neupro
Novel drug target	Established target
Mechanism of Interaction	D2-like dopamine receptor agonist

Direct Interaction	yes
Mechanism of Interaction	D2-like dopamine receptor inverse agonist
Trial Name	-

Trial Name	bromocriptine mesylate,Cycloset, Ergoset
Novel drug target	Established target

Trial Name	lurasidone, SM-13496,Latuda
Novel drug target	Established target

Trial Name	ITI-007, ITI-722
Novel drug target	Established target
Mechanism of Interaction	Dopamine D2 receptor partial agonist

Trial Name	AZ-001, Staccato prochlorperazine
Novel drug target	Established target
Trial Name	buccal prochlorperazine maleate,Emezine

Trial Name	ziprasidone HCl, ziprasidone mesylate,Geodon, Zeldox
Novel drug target	Established target

Mechanism of Interaction	Dopamine receptor antagonist
Direct Interaction	yes
Novel drug target	Established target

Direct Interaction	yes
Mechanism of Interaction	Dopamine receptors; D2 & D3 partial agonist
Trial Name	pardoprunox, SLV 308

DRD2 Gene Record

DRD2 1813 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

Sources: PharmGKB TTD

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name - Novel drug target Established target Mechanism of Interaction Dopamine D2 receptor agonist

PMIDs: 18808942 12721865 18303487 8951172 12464354 12008749 11752352 11436517 15341508

Sources: TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 18808942 2860228 16842172 11752352 3828803 1674528 18691132 10516878 10641988

Sources: TdgClinicalTrial TEND PharmGKB TTD

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name JNJ-37822681 Novel drug target Established target

PMIDs: 22490380

Sources: TdgClinicalTrial TTD

Interaction Types & Directionality: modulator

Interaction Info: Novel drug target Established target Trial Name pridopidine, ACR-16,Huntexil Mechanism of Interaction Dopamine D2 receptor modulator

PMIDs: None found

Sources: TdgClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name Mirapex Novel drug target Established target

PMIDs: 18691132 10641988 11752352 9638397 22023785 9617505

Sources: TdgClinicalTrial TEND TTD

Interaction Types & Directionality: partial agonist (activating) agonist (activating) antagonist (inhibitory)

Interaction Info: Trial Name Abilify Novel drug target Established target Mechanism of Interaction Dopamine D2 receptor partial agonist

PMIDs: 9083792 17501690 11752352 16366516 16925992 16981227 9918131 28673279 20194480 10327430 991813 9858029 9713903 19900188 19582781 19158809 18926547 18687376 18583979 17105675 17087792 16973280 16513877 16123753 15830237 15694263 15567074 14610521 11920858 11505224 26346901

Sources: TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name JZP-7 Novel drug target Established target Trial Name ReQuip

PMIDs: 18808942 1683559 10446316 17573046 11752352 18691132 10641988 19557097

Sources: TdgClinicalTrial TEND PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9918131 9858029 28673279 20194480 18926547 17105675 16513877 15830237 15694263 11505224

Sources: PharmGKB

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Novel drug target Established target Trial Name -

PMIDs: 9353417 9577836 17016423 9342550 11752352

Sources: TdgClinicalTrial TEND TTD

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 11752352 11873706 17016423 17139284 6147851

Sources: TdgClinicalTrial TEND TTD

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Mechanism of Interaction Dopamine D2 receptor antagonist Direct Interaction yes

PMIDs: 11103886 16867246 20643630 15694263 11873706 3039860 11752352

Sources: ChemblInteractions TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 3783613

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16123753 10395223 9672901 19944883 19853839 1969501 19603545 19396436 19373123 19273465 19179847 18926547 18855532 18781857 18781856 1839129 18354387 18180754 18086475 17989061 17767146 15830237 15492764 15286066 15184239 15146457 15077009 12587665 11329406 10862524 10823405

Sources: PharmGKB

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Novel drug target Established target Trial Name AZ-004 Mechanism of Interaction D2-like dopamine receptor antagonist

PMIDs: 9570468 6239298 15694653 8665533 9342550 11752352 8101879

Sources: TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

PMIDs: 7498321 8797192 6149133 11873706 11752352 1674528 17111172 21421319

Sources: DTC

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 4889058 4861216 11752352 4887393

Sources: TdgClinicalTrial TEND TTD

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 18691132 11752352

Sources: TdgClinicalTrial TEND TTD

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 12010185 15894081 1683559 18970411 11752352

Interaction Types & Directionality:

n/a

Sources:
PharmGKB TTD

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Dopamine D2 receptor agonist

PMIDs:
18808942 12721865 18303487 8951172 12464354 12008749 11752352 11436517 15341508

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
18808942 2860228 16842172 11752352 3828803 1674528 18691132 10516878 10641988

Sources:
TdgClinicalTrial TEND PharmGKB TTD

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name JNJ-37822681

Novel drug target Established target

PMIDs:
22490380

Sources:
TdgClinicalTrial TTD

Interaction Types & Directionality:

modulator

Interaction Info:

Novel drug target Established target

Trial Name pridopidine, ACR-16,Huntexil

Mechanism of Interaction Dopamine D2 receptor modulator

PMIDs:
None found

Sources:
TdgClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name Mirapex

Novel drug target Established target

PMIDs:
18691132 10641988 11752352 9638397 22023785 9617505

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

partial agonist (activating)

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Trial Name Abilify

Novel drug target Established target

Mechanism of Interaction Dopamine D2 receptor partial agonist

PMIDs:
9083792 17501690 11752352 16366516 16925992 16981227 9918131 28673279 20194480 10327430 991813 9858029 9713903 19900188 19582781 19158809 18926547 18687376 18583979 17105675 17087792 16973280 16513877 16123753 15830237 15694263 15567074 14610521 11920858 11505224 26346901

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name JZP-7

Novel drug target Established target

Trial Name ReQuip

PMIDs:
18808942 1683559 10446316 17573046 11752352 18691132 10641988 19557097

Sources:
TdgClinicalTrial TEND PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
9918131 9858029 28673279 20194480 18926547 17105675 16513877 15830237 15694263 11505224

Sources:
PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
9353417 9577836 17016423 9342550 11752352

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
11752352 11873706 17016423 17139284 6147851

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Dopamine D2 receptor antagonist

Direct Interaction yes

PMIDs:
11103886 16867246 20643630 15694263 11873706 3039860 11752352

Sources:
ChemblInteractions TTD

Interaction Types & Directionality:

n/a

PMIDs:
3783613

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
16123753 10395223 9672901 19944883 19853839 1969501 19603545 19396436 19373123 19273465 19179847 18926547 18855532 18781857 18781856 1839129 18354387 18180754 18086475 17989061 17767146 15830237 15492764 15286066 15184239 15146457 15077009 12587665 11329406 10862524 10823405

Sources:
PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name AZ-004

Mechanism of Interaction D2-like dopamine receptor antagonist

PMIDs:
9570468 6239298 15694653 8665533 9342550 11752352 8101879

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality:

antagonist (inhibitory)

PMIDs:
7498321 8797192 6149133 11873706 11752352 1674528 17111172 21421319

Sources:
DTC

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
4889058 4861216 11752352 4887393

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
18691132 11752352

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
12010185 15894081 1683559 18970411 11752352

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
16135699 15357957 11752352

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
8748043 17535043 11752352 1822319

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor antagonist

Direct Interaction yes

Trial Name -

Trial Name	dexpramipexole, KNS-760704
Novel drug target	Established target

Trial Name	DM-1992
Novel drug target	Established target
Trial Name	entacapone/levodopa/carbidopa,Stalevo

Direct Interaction	yes
Mechanism of Interaction	Dopamine receptor agonist

1813	Entrez Gene Id
DRD2	Gene Symbol
ENSG00000149295	Ensembl Gene Id

DRD2	GENE_SYMBOL
D(2) dopamine receptor	UNIPROT
Dopamine D2 receptor	UNIPROT